

Julio S G Montaner

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5363961/publications.pdf>

Version: 2024-02-01

108
papers

3,423
citations

136950

32
h-index

168389

53
g-index

116
all docs

116
docs citations

116
times ranked

4521
citing authors

#	ARTICLE	IF	CITATIONS
1	Effect of Medication Adherence on Survival of HIV-Infected Adults Who Start Highly Active Antiretroviral Therapy When the CD4+ Cell Count Is 0.200 to 0.350 $\times 10^9$ cells/L. <i>Annals of Internal Medicine</i> , 2003, 139, 810.	3.9	323
2	Expansion of HAART Coverage Is Associated with Sustained Decreases in HIV/AIDS Morbidity, Mortality and HIV Transmission: The "HIV Treatment as Prevention" Experience in a Canadian Setting. <i>PLoS ONE</i> , 2014, 9, e87872.	2.5	272
3	Near real-time monitoring of HIV transmission hotspots from routine HIV genotyping: an implementation case study. <i>Lancet HIV</i> , 2016, 3, e231-e238.	4.7	168
4	Improved Virological Outcomes in British Columbia Concomitant with Decreasing Incidence of HIV Type 1 Drug Resistance Detection. <i>Clinical Infectious Diseases</i> , 2010, 50, 98-105.	5.8	114
5	Initiating Highly Active Antiretroviral Therapy and Continuity of HIV Care: The Impact of Incarceration and Prison Release on Adherence and HIV Treatment Outcomes. <i>Antiviral Therapy</i> , 2004, 9, 713-719.	1.0	104
6	The Impact of Clinical, Demographic and Risk Factors on Rates of HIV Transmission: A Population-based Phylogenetic Analysis in British Columbia, Canada. <i>Journal of Infectious Diseases</i> , 2015, 211, 926-935.	4.0	89
7	Changes in mortality rates and causes of death in a population-based cohort of persons living with and without HIV from 1996 to 2012. <i>BMC Infectious Diseases</i> , 2017, 17, 174.	2.9	87
8	A Pilot Study of Hydroxyurea among Patients with Advanced Human Immunodeficiency Virus (HIV) Disease Receiving Chronic Didanosine Therapy: Canadian HIV Trials Network Protocol 080. <i>Journal of Infectious Diseases</i> , 1997, 175, 801-806.	4.0	84
9	Antiviral effect of double and triple drug combinations amongst HIV-infected adults. <i>Aids</i> , 1998, 12, 279-284.	2.2	79
10	Suboptimal Biological Sampling as a Probable Cause of False-Negative COVID-19 Diagnostic Test Results. <i>Journal of Infectious Diseases</i> , 2020, 222, 899-902.	4.0	75
11	Reduced Magnitude and Durability of Humoral Immune Responses to COVID-19 mRNA Vaccines Among Older Adults. <i>Journal of Infectious Diseases</i> , 2022, 225, 1129-1140.	4.0	65
12	Humoral immune responses to COVID-19 vaccination in people living with HIV receiving suppressive antiretroviral therapy. <i>Npj Vaccines</i> , 2022, 7, 28.	6.0	64
13	High Levels of Heterogeneity in the HIV Cascade of Care across Different Population Subgroups in British Columbia, Canada. <i>PLoS ONE</i> , 2014, 9, e115277.	2.5	62
14	Mitochondrial Toxicity in the Era of HAART: Evaluating Venous Lactate and Peripheral Blood Mitochondrial DNA in HIV-Infected Patients Taking Antiretroviral Therapy. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2003, 34, S85-S90.	2.1	61
15	Expert consensus statement on the science of HIV in the context of criminal law. <i>Journal of the International AIDS Society</i> , 2018, 21, e25161.	3.0	59
16	Burden of HIV Infection Among Aboriginal Injection Drug Users in Vancouver, British Columbia. <i>American Journal of Public Health</i> , 2008, 98, 515-519.	2.7	56
17	Cohort Profile: Seek and Treat for the Optimal Prevention of HIV/AIDS in British Columbia (STOP) Tj ETQq1 1 0.784314 rgBT /Overlock 1.9 56	1.9	56
18	Adherence to Antiretroviral Therapy and Cd4 T-Cell Count Responses among HIV-Infected Injection Drug Users. <i>Antiviral Therapy</i> , 2004, 9, 229-235.	1.0	56

#	ARTICLE	IF	CITATIONS
19	Health-adjusted life expectancy in HIV-positive and HIV-negative men and women in British Columbia, Canada: a population-based observational cohort study. <i>Lancet HIV</i> , 2017, 4, e270-e276.	4.7	51
20	The Effects of Opioid Substitution Treatment and Highly Active Antiretroviral Therapy on the Cause-Specific Risk of Mortality Among HIV-Positive People Who Inject Drugs. <i>Clinical Infectious Diseases</i> , 2015, 61, 1157-1165.	5.8	48
21	Denial of prescription analgesia among people who inject drugs in a Canadian setting. <i>Drug and Alcohol Review</i> , 2015, 34, 221-228.	2.1	47
22	Factors Associated with Public Injecting Among Users of Vancouver's Supervised Injection Facility. <i>American Journal of Drug and Alcohol Abuse</i> , 2007, 33, 319-325.	2.1	45
23	Global Origin and Transmission of Hepatitis C Virus Nonstructural Protein 3 Q80K Polymorphism. <i>Journal of Infectious Diseases</i> , 2015, 211, 1288-1295.	4.0	44
24	The spread of hepatitis C virus genotype 1a in North America: a retrospective phylogenetic study. <i>Lancet Infectious Diseases</i> , 2016, 16, 698-702.	9.1	41
25	Gender Inequities in Quality of Care among HIV-Positive Individuals Initiating Antiretroviral Treatment in British Columbia, Canada (2000-2010). <i>PLoS ONE</i> , 2014, 9, e92334.	2.5	40
26	Individual, Social, and Environmental Factors Associated with Initiating Methamphetamine Injection: Implications for Drug Use and HIV Prevention Strategies. <i>Prevention Science</i> , 2011, 12, 173-180.	2.6	39
27	Adherence and plasma HIV RNA response to antiretroviral therapy among HIV-seropositive injection drug users in a Canadian setting. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2011, 23, 980-987.	1.2	39
28	Gender Differences in Clinical Outcomes among HIV-Positive Individuals on Antiretroviral Therapy in Canada: A Multisite Cohort Study. <i>PLoS ONE</i> , 2013, 8, e83649.	2.5	39
29	Clinical uses of non-nucleoside reverse transcriptase inhibitors. <i>Reviews in Medical Virology</i> , 2000, 10, 217-229.	8.3	37
30	Trends in Awareness and Use of HIV PrEP Among Gay, Bisexual, and Other Men who have Sex with Men in Vancouver, Canada 2012-2016. <i>AIDS and Behavior</i> , 2018, 22, 3550-3565.	2.7	37
31	Cost-effectiveness of population-level expansion of highly active antiretroviral treatment for HIV in British Columbia, Canada: a modelling study. <i>Lancet HIV</i> , 2015, 2, e393-e400.	4.7	36
32	Circumstances of First Injection Among Illicit Drug Users Accessing a Medically Supervised Safer Injection Facility. <i>American Journal of Public Health</i> , 2007, 97, 1228-1230.	2.7	33
33	Associations of substance use, psychosis, and mortality among people living in precarious housing or homelessness: A longitudinal, community-based study in Vancouver, Canada. <i>PLoS Medicine</i> , 2020, 17, e1003172.	8.4	32
34	Availability of nutritional support services in HIV care and treatment sites in sub-Saharan African countries. <i>Public Health Nutrition</i> , 2012, 15, 938-947.	2.2	31
35	Cohort Profile: HAART Observational Medical Evaluation and Research (HOMER) Cohort. <i>International Journal of Epidemiology</i> , 2015, 44, 58-67.	1.9	31
36	Relative effects of antiretroviral therapy and harm reduction initiatives on HIV incidence in British Columbia, Canada, 1996-2013: a modelling study. <i>Lancet HIV</i> , 2017, 4, e303-e310.	4.7	31

#	ARTICLE	IF	CITATIONS
37	People With Human Immunodeficiency Virus Receiving Suppressive Antiretroviral Therapy Show Typical Antibody Durability After Dual Coronavirus Disease 2019 Vaccination and Strong Third Dose Responses. <i>Journal of Infectious Diseases</i> , 2023, 227, 838-849.	4.0	31
38	Suicide mortality among people accessing highly active antiretroviral therapy for HIV/AIDS in British Columbia: a retrospective analysis. <i>CMAJ Open</i> , 2015, 3, E140-E148.	2.4	30
39	The impact of scaling-up combination antiretroviral therapy on patterns of mortality among HIV-positive persons in British Columbia, Canada. <i>Journal of the International AIDS Society</i> , 2015, 18, 20261.	3.0	29
40	Progress towards the United Nations 90-90-90 and 95-95-95 targets: the experience in British Columbia, Canada. <i>Journal of the International AIDS Society</i> , 2017, 20, e25011.	3.0	28
41	Does This Adult Patient Have Early HIV Infection?. <i>JAMA - Journal of the American Medical Association</i> , 2014, 312, 278.	7.4	26
42	Modelling the Potential Economic Impact of Viral Load-Driven Triple Drug Combination Antiretroviral Therapy. <i>Pharmacoeconomics</i> , 1998, 13, 697-705.	3.3	25
43	Late initiation of combination antiretroviral therapy in Canada: a call for a national public health strategy to improve engagement in HIV care. <i>Journal of the International AIDS Society</i> , 2015, 18, 20024.	3.0	22
44	Identifying self-perceived HIV-related stigma in a population accessing antiretroviral therapy. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2013, 25, 95-102.	1.2	21
45	Evaluation of Nasopharyngeal Swab Collection Techniques for Nucleic Acid Recovery and Participant Experience: Recommendations for COVID-19 Diagnostics. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa488.	0.9	21
46	Characterization of Reverse Transcriptase Activity and Susceptibility to Other Nucleosides of AZT-Resistant Variants of HIV-1. <i>Annals of the New York Academy of Sciences</i> , 1990, 616, 346-355.	3.8	20
47	Safety and Efficacy of Once-Daily Nevirapine Dosing: A Multicohort Study. <i>Antiviral Therapy</i> , 2009, 14, 931-938.	1.0	20
48	Health and social harms associated with crystal methamphetamine use among street-involved youth in a Canadian setting. <i>American Journal on Addictions</i> , 2014, 23, 393-398.	1.4	20
49	Relationship between hunger, adherence to antiretroviral therapy and plasma HIV RNA suppression among HIV-positive illicit drug users in a Canadian setting. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2014, 26, 459-465.	1.2	19
50	Age, Adherence and Injection Drug use Predict Virological Suppression among Men and Women Enrolled in a Population-Based Antiretroviral Drug Treatment Programme. <i>Antiviral Therapy</i> , 2003, 8, 569-576.	1.0	19
51	Association between Childhood Physical Abuse, Unprotected Receptive Anal Intercourse and HIV Infection among Young Men Who Have Sex with Men in Vancouver, Canada. <i>PLoS ONE</i> , 2014, 9, e100501.	2.5	18
52	“The way I see it” the effect of stigma and depression on self-perceived body image among HIV-positive individuals on treatment in British Columbia, Canada. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2011, 23, 1456-1466.	1.2	17
53	High rates of lifetime and recent violence observed among harder-to-reach women living with HIV. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2014, 26, 587-594.	1.2	17
54	Factors associated with optimal pharmacy refill adherence for antiretroviral medications and plasma HIV RNA non-detectability among HIV-positive crack cocaine users: a prospective cohort study. <i>BMC Infectious Diseases</i> , 2016, 16, 455.	2.9	17

#	ARTICLE	IF	CITATIONS
55	Cohort profile: the Comparative Outcomes And Service Utilization Trends (COAST) Study among people living with and without HIV in British Columbia, Canada. <i>BMJ Open</i> , 2018, 8, e019115.	1.9	17
56	SARS-CoV-2 RNA Quantification Using Droplet Digital RT-PCR. <i>Journal of Molecular Diagnostics</i> , 2021, 23, 907-919.	2.8	17
57	Factors associated with sex-trade involvement among female injection drug users in a Canadian setting. <i>Addiction Research and Theory</i> , 2005, 13, 193-199.	1.9	16
58	The effect of history of injection drug use and alcoholism on HIV disease progression. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2014, 26, 123-129.	1.2	16
59	The need for standardisation of the HIV continuum of care. <i>Lancet HIV</i> , 2015, 2, e225-e226.	4.7	16
60	The Impact of Treatment as Prevention on the HIV Epidemic in British Columbia, Canada. <i>Current HIV/AIDS Reports</i> , 2020, 17, 77-87.	3.1	16
61	Prevalence and clinical implications of insertions in the HIV-1 p6 ^{Gag} N-terminal region in drug-naive individuals initiating antiretroviral therapy. <i>Antiviral Therapy</i> , 2003, 8, 91-96.	1.0	16
62	Total Lymphocyte Count as a Possible Surrogate of Cd4 Cell Count to Prioritize Eligibility for Antiretroviral Therapy among HIV-Infected Individuals in Resource-Limited Settings. <i>Antiviral Therapy</i> , 2003, 8, 379-384.	1.0	16
63	HIV antiviral drug resistance: patient comprehension. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2010, 22, 816-826.	1.2	15
64	Update on Current Evidence for Hepatitis C Therapeutic Options in HCV Mono-infected Patients. <i>Current Infectious Disease Reports</i> , 2016, 18, 22.	3.0	14
65	Stavudine plus Lamivudine in Advanced Human Immunodeficiency Virus Disease: A Short-Term Pilot Study. <i>Journal of Infectious Diseases</i> , 1997, 176, 1156-1160.	4.0	13
66	Short Communication: HIV VprR77Q Mutation Does Not Influence Clinical Response of Individuals Initiating Highly Active Antiretroviral Therapy. <i>AIDS Research and Human Retroviruses</i> , 2006, 22, 615-618.	1.1	13
67	Incidence of select chronic comorbidities among a population-based cohort of HIV-positive individuals receiving highly active antiretroviral therapy. <i>Current Medical Research and Opinion</i> , 2019, 35, 1955-1963.	1.9	12
68	CD4 T-cell recovery after initiation of antiretroviral therapy in a resource-limited setting: a prospective cohort analysis. <i>Antiviral Therapy</i> , 2013, 19, 31-39.	1.0	11
69	Achieving the 90-90-90 target: incentives for HIV testing. <i>Lancet Infectious Diseases</i> , 2016, 16, 1215-1216.	9.1	11
70	Crystal Methamphetamine Use and Initiation among Gay, Bisexual, and Other Men Who Have Sex with Men Living with HIV in a Treatment as Prevention Environment. <i>Substance Use and Misuse</i> , 2020, 55, 2428-2437.	1.4	11
71	Asthma Mortality in Canada, 1946 to 1990. <i>Canadian Respiratory Journal</i> , 1995, 2, 61-66.	1.6	10
72	The Impact of Implementing a Test, Treat and Retain HIV Prevention Strategy in Atlanta among Black Men Who Have Sex with Men with a History of Incarceration: A Mathematical Model. <i>PLoS ONE</i> , 2015, 10, e0123482.	2.5	10

#	ARTICLE	IF	CITATIONS
73	Characterizing Human Immunodeficiency Virus Antiretroviral Therapy Interruption and Resulting Disease Progression Using Population-Level Data in British Columbia, 1996–2015. <i>Clinical Infectious Diseases</i> , 2017, 65, 1496-1503.	5.8	10
74	Use of injectable hormonal contraception and HSV-2 acquisition in a cohort of female sex workers in Vancouver, Canada. <i>Sexually Transmitted Infections</i> , 2017, 93, 284-289.	1.9	9
75	Harder-to-reach people living with HIV experiencing high prevalence of all-type mental health disorder diagnosis. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2017, 29, 696-704.	1.2	9
76	Factors associated with delayed and late ART initiation among people living with HIV in BC: results from the engage study. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2019, 31, 885-892.	1.2	9
77	Predictors of liver-related death among people who inject drugs in Vancouver, Canada: a 15-year prospective cohort study. <i>Journal of the International AIDS Society</i> , 2014, 17, 19296.	3.0	8
78	The impact of unstable housing on emergency department use in a cohort of HIV-positive people in a Canadian setting. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2014, 26, 53-64.	1.2	8
79	Detection of HIV transmission hotspots in British Columbia, Canada: A novel framework for the prioritization and allocation of treatment and prevention resources. <i>EBioMedicine</i> , 2019, 48, 405-413.	6.1	8
80	Home is where the HAART is: an examination of factors affecting neighbourhood perceptions among people with HIV/AIDS on antiretroviral therapy. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2011, 23, 245-251.	1.2	7
81	Comparing the efficacy of efavirenz and boosted lopinavir using viremia copy-years. <i>Journal of the International AIDS Society</i> , 2014, 17, 18617.	3.0	7
82	Increases in CD4+ T-cell count at antiretroviral therapy initiation among HIV-positive illicit drug users during a treatment-as-prevention initiative in Canada. <i>Antiviral Therapy</i> , 2017, 22, 403-411.	1.0	7
83	Comparison of atazanavir/ritonavir and darunavir/ritonavir based antiretroviral therapy for antiretroviral naïve patients. <i>BMC Infectious Diseases</i> , 2017, 17, 266.	2.9	7
84	Declining Mortality Rates in HIV-Infected People Who Inject Drugs During a Seek-and-Treat Initiative in Vancouver, Canada, 1996–2014: A Prospective Cohort Study. <i>Journal of Infectious Diseases</i> , 2018, 217, 64-68.	4.0	7
85	Structural Design and Data Requirements for Simulation Modelling in HIV/AIDS: A Narrative Review. <i>Pharmacoeconomics</i> , 2019, 37, 1219-1239.	3.3	7
86	Diminished HIV-1 Sensitivity to Stavudine in Patients on Prolonged Therapy Occurs Only at Low Levels and Cannot be Attributed to Any Single Amino Acid Substitution in Reverse Transcriptase. <i>Antiviral Therapy</i> , 1998, 3, 177-182.	1.0	7
87	Association of the CCR5 ^{Δ32} Mutation with Clinical Response and >5-year Survival following Initiation of First Triple Antiretroviral Regimen. <i>Antiviral Therapy</i> , 2005, 10, 849-853.	1.0	7
88	Trends in discharges from the HIV/AIDS ward at a tertiary Canadian Hospital from 2005 to 2014. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2018, 30, 1099-1106.	1.2	6
89	Factors Associated with Mood Disorder Diagnosis Among a Population Based Cohort of Men and Women Living With and Without HIV in British Columbia Between 1998 and 2012. <i>AIDS and Behavior</i> , 2018, 22, 1530-1540.	2.7	6
90	Efficacy, safety and pharmacokinetics of once-daily saquinavir soft-gelatin capsule/ritonavir in antiretroviral-naïve, HIV-infected patients. <i>MedGenMed: Medscape General Medicine</i> , 2006, 8, 36.	0.2	6

#	ARTICLE	IF	CITATIONS
91	The opioid crisis is driving mortality among under-served people living with HIV in British Columbia, Canada. <i>BMC Public Health</i> , 2021, 21, 680.	2.9	5
92	Concordance of HIV transmission risk factors elucidated using viral diversification rate and phylogenetic clustering. <i>Evolution, Medicine and Public Health</i> , 2021, 9, 338-348.	2.5	5
93	Social-structural factors associated with supportive service use among a cohort of HIV-positive individuals on antiretroviral therapy. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2013, 25, 937-947.	1.2	3
94	Factors associated with low neighborhood cohesion among women living with HIV impacted by social-structural inequities in British Columbia. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2018, 30, 318-324.	1.2	3
95	Can the combination of TasP and PrEP eliminate HIV among MSM in British Columbia, Canada?. <i>Epidemics</i> , 2021, 35, 100461.	3.0	3
96	Transmission of Drug-Resistant HIV-1 from an Infected Individual to a Caregiver. <i>Antiviral Therapy</i> , 2007, 12, 1139-1144.	1.0	3
97	Management of HIV-infected patients with multidrug-resistant virus. <i>Current Infectious Disease Reports</i> , 2002, 4, 259-265.	3.0	2
98	Clinical uses of non-nucleoside reverse transcriptase inhibitors. <i>Reviews in Medical Virology</i> , 2000, 10, 217-229.	8.3	2
99	A latent class analysis of sexual and romantic relationships among HIV-positive and HIV-negative gay and bisexual men in Vancouver. <i>Canadian Journal of Human Sexuality</i> , 2017, 26, 78-96.	1.6	2
100	HIV treatment strategies that can weather future challenges. <i>Lancet Infectious Diseases</i> , The, 2014, 14, 534-535.	9.1	1
101	Predicting Virological Response to HIV Treatment Over Time: A Tool for Settings With Different Definitions of Virological Response. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019, 81, 207-215.	2.1	1
102	Chronic Hepatitis B Infection Among Preexposure Prophylaxis Users Enrolled in a Population-Based Program in British Columbia, Canada. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab492.	0.9	1
103	Antiretroviral treatment initiation – Authors' reply. <i>Lancet Infectious Diseases</i> , The, 2014, 14, 1176-1177.	9.1	0
104	Heightened epidemic in men who have sex with men in Brazil. <i>Lancet HIV</i> , the, 2016, 3, e454-e455.	4.7	0
105	Assessing the relationship between physician availability and viral load suppression in British Columbia. <i>Canadian Geographer / Geographie Canadien</i> , 2018, 62, 120-129.	1.5	0
106	Incorporation of ANTI-HHV-8 Agents as Targeted Therapy for the Treatment of HIV-Associated Primary Effusion Lymphoma.. <i>Blood</i> , 2009, 114, 4768-4768.	1.4	0
107	Neighbourhood-level material deprivation and response to combination antiretroviral therapy in the Canadian Observational Cohort (CANOC): a longitudinal cohort study. <i>CMAJ Open</i> , 2022, 10, E183-E189.	2.4	0
108	Antiretroviral Effect of Two Different Dose Regimens of Ritonavir and Saquinavir on HIV-Infected Adults in a Population-Based Setting. <i>Antiviral Therapy</i> , 1999, 4, 151-156.	1.0	0